Andrew Yee

Dr. Andrew Yee


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2015 in Blood
Verified
Journal Article
Closed access
PDF file
AYAndrew Yee
Andrew Yee
AOAustin N. Oleskie
Austin N. Oleskie
ADAnne M. Dosey
Anne M. Dosey
CKColin A. Kretz
Colin A. Kretz
RGRobert D. Gildersleeve
Robert D. Gildersleeve
GSGeorgios Skiniotis
Georgios Skiniotis
Binding to the von Willebrand factor (VWF) D′D3 domains protects factor VIII (FVIII) from rapid clearance. We performed single-particle electron microscopy (EM) analysis of negatively stained specimens to examine the architecture of D′D3 alone and in complex with FVIII. The D′D3 dimer ([D′D3]2) comprises 2 antiparallel D3 monomers with flexibly attached protrusions of D′. FVIII-VWF association is primarily established between the FVIII C1 domain and the VWF D′ domain, whereas weaker interactions appear to be mediated between both FVIII C domains and the VWF D3 core. Modeling the FVIII structure into the three-dimensional EM reconstructions of [D′D3]2-FVIII ternary and quaternary complexes indicates conformational rearrangements of the FVIII C domains compared with their disposition in the unbound state. These results illustrate the cooperative plasticity between VWF and FVIII that coordinate their high-affinity interaction. Key Points The VWF D′ domains are flexibly tethered entities projecting outside antiparallel dimers of the VWF D3 domain. Extensive interactions between the VWF D′ domain and primarily the FVIII C1 domain mediate VWF-FVIII association.

24 July 2019 in Molecules
Verified
Journal Article
Open access
PDF file
YAYathreb Asaad
Yathreb Asaad
MEMark Epshtein
Mark Epshtein
AYAndrew Yee
Andrew Yee
NKNetanel Korin
Netanel Korin
In arterial thrombosis, von Willebrand factor (VWF) bridges platelets to sites of vascular injury. The adhesive properties of VWF are controlled by its different domains, which may be engineered into ligands for targeting nanoparticles to vascular injuries. Here, we functionalized 200 nm polystyrene nanoparticles with the VWF-A1 domain and studied their spatial adhesion to collagen or collagen-VWF coated, real-sized coronary stenosis models under physiological flow. When VWF-A1 nano-particles (A1-NPs) were perfused through a 75% stenosis model coated with collagen-VWF, the particles preferentially adhered at the post stenotic region relative to the pre-stenosis region while much less adhesion was detected at the stenosis neck (~ 65-fold less). When infused through collagen-coated models or when the A1 coating density of nanoparticles was reduced by 100-fold, the enhanced adhesion at the post-stenotic site was abolished. In a 60% stenosis model, the adhesion of A1-NPs to collagen-VWF-coated models depended on the location examined within the stenosis. Altogether, our results indicate that VWF-A1 NPs exhibit a flow-structure dependent adhesion to VWF and illustrate the important role of studying cardiovascular nano-medicines in settings that closely model the size, geometry, and hemodynamics of pathological environments.

26 July 2022 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MBMonica Bray
Monica Bray
MGMelda A. Guzel
Melda A. Guzel
FLFong Lam
Fong Lam
AYAndrew Yee
Andrew Yee
MCMiguel A. Cruz
Miguel A. Cruz
RRRolando E. Rumbaut
Rolando E. Rumbaut

28 July 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
AYAndrew Yee
Andrew Yee
MDManhong Dai
Manhong Dai
SCStacy E. Croteau
Stacy E. Croteau
JSJordan A. Shavit
Jordan A. Shavit
SPSteven W. Pipe
Steven W. Pipe
DGDavid Ginsburg
David Ginsburg

9 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AYAndrew Yee
Andrew Yee
MDManhong Dai
Manhong Dai
SCStacy E. Croteau
Stacy E. Croteau
JSJordan A. Shavit
Jordan A. Shavit
SPSteven W. Pipe
Steven W. Pipe
DGDavid Ginsburg
David Ginsburg
Summary: Background: Correction of von Willebrand factor (VWF) deficiency with replacement products containing VWF can lead to the development of anti-VWF alloantibodies (i.e., VWF inhibitors) in patients with severe von Willebrand disease (VWD). Objective: Locate inhibitor-reactive regions within VWF using phage display. Methods: We screened a phage library displaying random, overlapping fragments covering the full length VWF protein sequence for binding to a commercial anti-VWF antibody or to immunoglobulins from three type 3 VWD patients who developed VWF inhibitors in response to treatment with plasma-derived VWF. Immunoreactive phage clones were identified and quantified by next generation DNA sequencing (NGS). Results: NGS markedly increased the number of phage analyzed for locating immunoreactive regions within VWF following a single round of selection and identified regions not recognized in previous reports using standard phage display methods. Extending this approach to characterize VWF inhibitors from three type 3 VWD patients (including two siblings homozygous for the same VWF gene deletion) revealed patterns of immunoreactivity distinct from the commercial antibody and between unrelated patients, though with notable areas of overlap. Alloantibody reactivity against the VWF propeptide is consistent with incomplete removal of the propeptide from plasma-derived VWF replacement products. Conclusion: These results demonstrate the utility of phage display and NGS to characterize diverse anti-VWF antibody reactivities.

23 March 2023 in Blood
Verified
Journal Article
Closed access
PDF file
AYAndrew Yee
Andrew Yee
In this issue of Blood, Tischer et al1 add to the growing pool of evidence that allostery within von Willebrand factor (VWF) regulates platelet adhesion.